Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications.
about
A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancersPractical management of patients with chronic myeloid leukemia.Interpreting molecular monitoring results and international standardization in chronic myeloid leukemia.del(15q) is a recurrent minor-route cytogenetic abnormality in the clonal evolution of chronic myelogenous leukemia.Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia.Major molecular response in CML patients treated with tyrosine kinase inhibitors: the paradigm for monitoring targeted cancer therapySuboptimal responses in chronic myeloid leukemia: implications and management strategiesChronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.Disease acceptance and adherence to imatinib in Taiwanese chronic myeloid leukaemia outpatients.Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management.Minimal residual disease testing in hematologic malignancies and solid cancer.Allogeneic stem cell transplantation for patients with chronic myeloid leukemia: risk stratified approach with a long-term follow-up.Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring.Lower than expected cytogenetic and molecular response to imatinib in Mexican patients with chronic myelogenous leukemia.Response to tyrosine kinase inhibitors in chronic myeloid leukemia: experience from a west Asian developing country.A comparison of therapeutic dosages of decitabine in treating myelodysplastic syndrome: a meta-analysis.
P2860
Q26743743-792EF3E4-D800-4DEF-B55B-D717A6AC9520Q33849146-8468FABE-A604-451A-A40F-11426C0A39C8Q33885583-C843A903-41BA-4C8E-BF74-60F16A8FA23CQ34204486-F0072D37-F3C7-442D-8692-7915036D5366Q34272962-40E72A0F-C2CA-41DC-9CB2-9756CA142047Q35584176-E9F3CDF6-AD43-4344-8C54-515FBC158F0DQ36144079-B87B2127-E74F-46F6-BF42-5DB13F90CDF2Q37163550-D89D0B07-5E1A-4C2A-933D-5DBC9EBE1E39Q37471683-576A0B93-5307-419F-8F48-5B9C99D3BB38Q38204330-193454D1-6836-40B4-AFE9-D387FF2B26A9Q38220970-421FC387-ACA1-41E1-AA83-DAB855B0C2D3Q39202778-A38D73AC-F982-4C09-8F3F-A9D658520407Q40957470-F9F410CD-5E10-49FA-A9E7-5AF31FBFBB51Q44703351-51B750B4-5E83-41C0-A7B5-0BA224D5108BQ54333450-DAD11EC2-1589-4B20-B25E-0392610E8501Q54363269-E7476997-D1C5-4629-B1F1-842A6AF10ADA
P2860
Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Molecular monitoring in chroni ...... s and prognostic implications.
@en
Molecular monitoring in chroni ...... s and prognostic implications.
@nl
type
label
Molecular monitoring in chroni ...... s and prognostic implications.
@en
Molecular monitoring in chroni ...... s and prognostic implications.
@nl
prefLabel
Molecular monitoring in chroni ...... s and prognostic implications.
@en
Molecular monitoring in chroni ...... s and prognostic implications.
@nl
P2860
P50
P356
P1433
P1476
Molecular monitoring in chroni ...... s and prognostic implications.
@en
P2860
P304
P356
10.1002/CNCR.23427
P407
P577
2008-05-01T00:00:00Z